MOA
MCID: OLG006
MIFTS: 35

Oligoastrocytoma (MOA)

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Oligoastrocytoma

MalaCards integrated aliases for Oligoastrocytoma:

Name: Oligoastrocytoma 20 58 29 17
Mixed Oligoastrocytoma 58 70
Mixed Oligodendroglioma-Astrocytoma 70
Oligoastrocytoma Mixed 54
Moa 58

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

ICD10 via Orphanet 33 C71.9
UMLS via Orphanet 71 C0280793
Orphanet 58 ORPHA251656
UMLS 70 C0280793 C0547065

Summaries for Oligoastrocytoma

GARD : 20 Oligoastrocytoma is a brain tumor that forms when two types of cells in the brain, called oligodendrocytes and astrocytes, rapidly increase in number to form a mass. These brain cells are known as glial cells, which normally protect and support nerve cells in the brain. Because an oligoastrocytoma is made up of a combination of two cell types, it is known as a mixed glioma. Oligoastrocytomas usually occur in a part of the brain called the cerebrum and are diagnosed in adults between the ages of 30 and 50. The exact cause of this condition is unknown.

MalaCards based summary : Oligoastrocytoma, also known as mixed oligoastrocytoma, is related to anaplastic oligoastrocytoma and anaplastic oligodendroglioma, and has symptoms including seizures and headache. An important gene associated with Oligoastrocytoma is IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2). The drugs Temozolomide and Carmustine have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and spinal cord, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 73 Oligoastrocytomas are a subset of brain tumors that present with an appearance of mixed glial cell... more...

Related Diseases for Oligoastrocytoma

Diseases related to Oligoastrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 90)
# Related Disease Score Top Affiliating Genes
1 anaplastic oligoastrocytoma 32.1 PMS2 IDH2
2 anaplastic oligodendroglioma 30.3 MGMT IDH2
3 malignant astrocytoma 30.0 MGMT IDH2 GFAP
4 low grade glioma 29.9 MGMT IDH2
5 mixed glioma 29.7 MGMT IDH2 GFAP
6 glioblastoma 29.4 MGMT IDH2 GFAP
7 high grade glioma 29.4 MGMT IDH2 GFAP
8 oligodendroglioma 29.3 PMS2 MGMT IDH2 HSPG2 GFAP
9 diffuse astrocytoma 29.1 MGMT IDH2 GFAP
10 anaplastic astrocytoma 29.0 PMS2 MGMT IDH2 GFAP
11 brain cancer 28.6 PMS2 MGMT IDH2 GFAP
12 glioma susceptibility 1 10.4
13 glioma 10.2
14 glial tumor 10.2
15 spinal cord oligodendroglioma 10.0 MGMT GFAP
16 gliofibroma 10.0 MGMT GFAP
17 anaplastic ganglioglioma 10.0 PMS2 GFAP
18 cellular ependymoma 10.0 MGMT GFAP
19 high grade ependymoma 10.0 MGMT GFAP
20 cerebral ventricle cancer 10.0 MGMT GFAP
21 cerebrum cancer 10.0 MGMT GFAP
22 supratentorial cancer 10.0 MGMT GFAP
23 pleomorphic xanthoastrocytoma 9.9 MGMT GFAP
24 neuroma 9.9 MGMT GFAP
25 infratentorial cancer 9.9 MGMT GFAP
26 pituitary carcinoma 9.9 PMS2 MGMT
27 gemistocytic astrocytoma 9.8 IDH2 GFAP
28 adult brain stem glioma 9.8 MGMT IDH2
29 pilocytic astrocytoma 9.8 MGMT GFAP
30 childhood oligodendroglioma 9.8 MGMT IDH2
31 mixed oligodendroglioma-astrocytoma 9.8 MGMT IDH2
32 multiple sclerosis 9.8
33 medulloblastoma 9.8
34 syringomyelia, noncommunicating isolated 9.8
35 mismatch repair cancer syndrome 1 9.8
36 autism x-linked 2 9.8
37 ataxia and polyneuropathy, adult-onset 9.8
38 leukemia, acute myeloid 9.8
39 meningioma, familial 9.8
40 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.8
41 leukemia, acute lymphoblastic 9.8
42 tumor predisposition syndrome 9.8
43 cutaneous telangiectasia and cancer syndrome, familial 9.8
44 hypophosphatemia 9.8
45 focal dystonia 9.8
46 cerebellar medulloblastoma 9.8
47 scoliosis 9.8
48 myelomeningocele 9.8
49 childhood acute myeloid leukemia 9.8
50 transverse myelitis 9.8

Graphical network of the top 20 diseases related to Oligoastrocytoma:



Diseases related to Oligoastrocytoma

Symptoms & Phenotypes for Oligoastrocytoma

UMLS symptoms related to Oligoastrocytoma:


seizures; headache

GenomeRNAi Phenotypes related to Oligoastrocytoma according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 9.47 PMS2
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-105 9.47 PMS2
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-111 9.47 MGMT
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 9.47 PMS2
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.47 PMS2
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-161 9.47 PMS2
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-28 9.47 PMS2
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-37 9.47 MGMT
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-56 9.47 PMS2
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-59 9.47 MGMT PMS2
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-63 9.47 PMS2
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 9.47 MGMT
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-98 9.47 PMS2

Drugs & Therapeutics for Oligoastrocytoma

Drugs for Oligoastrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 59)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Temozolomide Approved, Investigational Phase 3 85622-93-1 5394
2
Carmustine Approved, Investigational Phase 3 154-93-8 2578
3
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
4
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
5
tannic acid Approved Phase 3 1401-55-4
6 interferons Phase 3
7 Interferon-alpha Phase 3
8 Alkylating Agents Phase 3
9
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
10
carbamide peroxide Approved Phase 2 124-43-6
11
Palbociclib Approved, Investigational Phase 2 571190-30-2 11431660 5005498 5330286
12
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
13
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
14
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
15
Lenograstim Approved, Investigational Phase 2 135968-09-1
16
Mechlorethamine Approved, Investigational Phase 1, Phase 2 51-75-2 4033
17
Melphalan Approved Phase 1, Phase 2 148-82-3 4053 460612
18
Mannitol Approved, Investigational Phase 1, Phase 2 69-65-8 453 6251
19
Etoposide Approved Phase 1, Phase 2 33419-42-0 36462
20
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 498142 38904
21
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
22
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
23
Trioxsalen Approved Phase 2 3902-71-4 5585
24
Phenylalanine Approved, Investigational, Nutraceutical Phase 1, Phase 2 63-91-2 6140
25
Molgramostim Investigational Phase 2 99283-10-0
26 Protein Kinase Inhibitors Phase 1, Phase 2
27 topoisomerase I inhibitors Phase 2
28 Imatinib Mesylate Phase 1, Phase 2 220127-57-1 123596
29 Antirheumatic Agents Phase 2
30 Antineoplastic Agents, Immunological Phase 2
31 Anti-Infective Agents Phase 1, Phase 2
32 Antidotes Phase 1, Phase 2
33 Tubulin Modulators Phase 1, Phase 2
34 Antimitotic Agents Phase 1, Phase 2
35 Etoposide phosphate Phase 1, Phase 2
36 Chelating Agents Phase 1, Phase 2
37 Antioxidants Phase 1, Phase 2
38 Anti-Bacterial Agents Phase 1, Phase 2
39 Immunosuppressive Agents Phase 1, Phase 2
40 diuretics Phase 1, Phase 2
41 sodium thiosulfate Phase 1, Phase 2
42 Protective Agents Phase 1, Phase 2
43 Immunologic Factors Phase 1, Phase 2
44 Podophyllotoxin Phase 1, Phase 2 518-28-5
45 Nitrogen Mustard Compounds Phase 1, Phase 2
46 Antitubercular Agents Phase 1, Phase 2
47 Keratolytic Agents Phase 1, Phase 2
48 Histone Deacetylase Inhibitors Phase 2
49 Pharmaceutical Solutions Phase 2
50 Ether Phase 2

Interventional clinical trials:

(show all 21)
# Name Status NCT ID Phase Drugs
1 A Phase III Trial on Adjuvant Standard Temozolomide Chemotherapy With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Unknown status NCT01765088 Phase 3 Temozolomide;α-IFN
2 A Phase III Randomized Study (Phase I Closed) of Radiation Therapy and Temozolomide Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma And Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant) Completed NCT00004259 Phase 3 BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
3 A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard Treatment Recruiting NCT02629757 Phase 3 β-elemene
4 A Phase II Study of Prolonged Daily Temozolomide for Low-Grade Glioma Completed NCT00165360 Phase 2 Temozolomide
5 Phase II Trial of Continuous Dose Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma Completed NCT00362570 Phase 2 Temozolomide
6 A Phase II Study of Topotecan in Patients With Anaplastic Oligodendroglioma or Anaplastic Mixed Oligoastrocytoma Completed NCT00003372 Phase 2 topotecan hydrochloride
7 Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma Completed NCT00049127 Phase 1, Phase 2 Imatinib Mesylate
8 Primary Chemotherapy by BCNU-TMZ Combination in Newly Diagnosed Anaplastic Oligodendrocytic Tumors: Phase II Trial With Translational Molecular Analysis Completed NCT04755023 Phase 2 Bis-Chloroethyl-Nitroso-Urea (BCNU) withTemozolomide
9 Phase II Pilot, Prospective, Open Label, Multicenter CT, to Evaluate the Safety and Efficacy of Palbociclib (PD0332991), a Cyclin-dependent Kinase 4 and 6 (CDK4 and CDK6) Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved Completed NCT02530320 Phase 2 Palbociclib
10 The Efficacy and Safety of Temozolomide in Patients With Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: a Multicenter, Single-arm, Phase II Trial Completed NCT01847235 Phase 2 Temozolomide
11 A Phase II Trial Of Pre-Irradiation And Concurrent Temozolomide In Patients With Newly Diagnosed Anaplastic Oligodendrogliomas And Mixed Anaplastic Oligoastrocytomas Completed NCT00033280 Phase 2 temozolomide
12 CAMP 013:- Tandem Thiotepa Regimen For Selected Malignant Gliomas:1) Primary Or Recurrent Glioblastoma Multiforme (GBM); and 2) Recurrent Anaplastic Astrocytomas (AA), Oligodendrogliomas (O), Oligoastrocytomas (OA), Ependymomas And Primitive Neuroectodermal Tumors (PNET) That Have Either Progressed After Primary Therapy Or Are Refractory To Standard Chemotherapy Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
13 Phase I/II Study of Carboplatin, Melphalan and Etoposide Phosphate in Conjunction With Osmotic Opening of the Blood-Brain Barrier and Delayed Intravenous Sodium Thiosulfate Chemoprotection, in Previously Treated Subjects With Anaplastic Oligodendroglioma or Oligoastrocytoma Recruiting NCT00303849 Phase 1, Phase 2 Carboplatin;Etoposide;Etoposide Phosphate;Mannitol;Melphalan;Sodium Thiosulfate
14 Phase II Trial of Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory Glioblastoma Multiforme, Anaplastic Astrocytoma, and Anaplastic Oligoastrocytoma Recruiting NCT02800486 Phase 2 Intra-arterial Cetuximab;Intra-arterial Mannitol
15 A Phase 2 Study of Fluorescence Detection of Adult Primary Central Nervous System Tumors in Subjects Receiving Tozuleristide and Imaged With the Canvas System Not yet recruiting NCT04743310 Phase 2 tozuleristide
16 Phase II Trial of LBH589 (Panobinostat) in Adult Patients With Recurrent Malignant Gliomas Terminated NCT00848523 Phase 2 Panobinostat
17 A Phase II Study of Photodynamic Therapy (PDT) With Photofrin® (IND 104,613) For Recurrent High Grade Gliomas in Adults Terminated NCT01966809 Phase 2 Photofrin photodynamic therapy.
18 Phase I Study of Convection Enhanced Delivery (CED) of IL13-PE38QQR Infusion After Resection Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Supratentorial Malignant Glioma Completed NCT00089427 Phase 1 IL13-PE38QQR;Temozolomide with radiation therapy
19 Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors, A Feasibility Study Completed NCT01999270 Phase 1 Irinotecan;Bevacizumab
20 A Phase I Dose Escalation and Central Nervous System (CNS) Pharmacokinetic Study of the ErbB Family Inhibitor Afatinib in Patients With Recurrent or Progressive Brain Cancer Active, not recruiting NCT02423525 Phase 1 Afatinib
21 The Neural Basis of Language: A New Lighting. Study of Semantic Processing in MRI Mutimodale and Direct Electrical Stimulation Completed NCT02903784

Search NIH Clinical Center for Oligoastrocytoma

Genetic Tests for Oligoastrocytoma

Genetic tests related to Oligoastrocytoma:

# Genetic test Affiliating Genes
1 Oligoastrocytoma 29

Anatomical Context for Oligoastrocytoma

MalaCards organs/tissues related to Oligoastrocytoma:

40
Brain, Eye, Spinal Cord, Myeloid, Pituitary, Bone Marrow, Temporal Lobe

Publications for Oligoastrocytoma

Articles related to Oligoastrocytoma:

(show top 50) (show all 518)
# Title Authors PMID Year
1
Prognostic Role of EYA4 in Lower Grade Glioma with IDH1 Mutation and 1p19q Co-Deletion. 61
33631386 2021
2
Anaplastic oligoastrocytoma with dual genotype: A case report of a rare entity. 61
32893816 2020
3
[Diffuse Astrocytoma with Malignant Progression after Long-term Temozolomide Monotherapy:A Case Report]. 61
33071231 2020
4
Nuclear H3 K27me3 is retained in both components of dual genotype oligoastrocytoma. 61
32383207 2020
5
Risk Stratification in Low Grade Glioma: A Single Institutional Experience. 61
32859817 2020
6
A dual-genotype oligoastrocytoma with histologic, molecular, radiological and time-course features. 61
32690110 2020
7
Low expression of FOSL1 is associated with favorable prognosis and sensitivity to radiation/pharmaceutical therapy in lower grade glioma. 61
32245342 2020
8
Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma. 61
32293798 2020
9
Pediatric Kidney Transplantation in Perú: A Single-Center Initial Experience. 61
32115239 2020
10
Acute and chronic hemorrhage from radiation-induced cavernous malformation associated with late-delayed radiation necrosis in long surviving glioma patients: A case report. 61
31897165 2020
11
Incidence of Gliomas in Municipalities of Zenica - Doboj Canton in Bosnia and Herzegovina - A 10-Year Study. 61
32733763 2020
12
Early versus delayed postoperative radiotherapy for treatment of low-grade gliomas. 61
31958162 2020
13
Surgical treatment of low-grade brain tumors associated with epilepsy. 61
32448606 2020
14
Oligo-astrocytoma in LZTR1-related Noonan syndrome. 61
30664951 2020
15
The crystal structure of Capicua HMG-box domain complexed with the ETV5-DNA and its implications for Capicua-mediated cancers. 61
31323153 2019
16
Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG). 61
31165953 2019
17
The Applicability of Haarlem Integrated Diagnostic System in Diffuse Glial Tumors and Molecular Methods Affecting Prognosis 61
30592195 2019
18
The pan-cancer mutational landscape of the PPAR pathway reveals universal patterns of dysregulated metabolism and interactions with tumor immunity and hypoxia. 61
31215667 2019
19
Incidence trends of adult malignant brain tumors in Finland, 1990-2016. 61
30985227 2019
20
Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG). 61
31119479 2019
21
Brain cancer survival in Canada 1996-2008: effects of sociodemographic characteristics. 61
31285671 2019
22
von Willebrand Factor Gene Expression in Primary Lower Grade Glioma: Mutually Co-Occurring Mutations in von Willebrand Factor, ATRX, and TP53. 61
31062529 2019
23
Sequencing of Chemotherapy and Radiotherapy for Newly Diagnosed Anaplastic Oligodendroglioma and Oligoastrocytoma. 61
30601146 2019
24
A Pilot Study of Vaccine Therapy with Multiple Glioma Oncoantigen/Glioma Angiogenesis-Associated Antigen Peptides for Patients with Recurrent/Progressive High-Grade Glioma. 61
30791546 2019
25
Allergy may confer better survival on patients with gliomas. 61
30611004 2019
26
Comparison of Radiation Therapy Alone and Chemotherapy Alone for Low-Grade Gliomas without Surgical Resection. 61
30261385 2019
27
Engrailed 1 overexpression as a potential prognostic marker in Lower Grade Glioma. 61
31576231 2019
28
Molecular features and clinical outcomes in surgically treated low-grade diffuse gliomas in patients over the age of 60. 61
30498891 2019
29
Recurrent Glioma With Lineage Conversion From Oligodendroglioma to Astrocytoma in Two Cases. 61
31508376 2019
30
Neurosurgical therapy for Status Epilepticus in Oligoastrocytoma Patient: A case report. 61
30682510 2019
31
Successful treatment of a BRAF V600E-mutant extracranial metastatic anaplastic oligoastrocytoma with vemurafenib and everolimus. 61
30462564 2019
32
Impact of adjuvant treatments on survival in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup study. 61
30097825 2018
33
Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial. 61
29955793 2018
34
Age and surgical outcome of low-grade glioma in Sweden. 61
29900547 2018
35
Increased HSPG2 expression independently predicts poor survival in patients with oligoastrocytoma and oligodendroglioma. 61
30402850 2018
36
Possibility of venoarterial extracorporeal membranous oxygenator being a bridging therapy for hemodynamic deterioration of pulmonary tumor thrombotic microangiopathy prior to initiating chemotherapy: A case report. 61
30212945 2018
37
Diffuse low-grade glioma mimicking ischaemic infarct: a case report. 61
29384395 2018
38
Outcomes for Anaplastic Glioma Treated With Radiation Therapy With or Without Concurrent Temozolomide. 61
28301347 2018
39
Extracranial metastasis of anaplastic oligoastrocytoma. 61
30197798 2018
40
Correction to: SEOM clinical guidelines for anaplastic gliomas (2017). 61
29858734 2018
41
Multi-institutional study of treatment patterns in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup study. 61
29572674 2018
42
Threshold of the extent of resection for WHO Grade III gliomas: retrospective volumetric analysis of 122 cases using intraoperative MRI. 61
28885120 2018
43
Symptomatic Remote Cyst after BCNU Wafer Implantation for Malignant Glioma. 61
29780071 2018
44
A simple algorithmic approach using histology and immunohistochemistry for the current classification of adult diffuse glioma in a resource-limited set-up. 61
28801347 2018
45
The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas. 61
29218432 2018
46
WHO 2016 Classification of gliomas. 61
28815663 2018
47
SEOM clinical guideline of diagnosis and management of low-grade glioma (2017). 61
29124520 2018
48
SEOM clinical guidelines for anaplastic gliomas (2017). 61
29058264 2018
49
Intraoperative Squash and Touch Preparation Cytology of Brain Lesions Stained with H+E and Diff-Quik™: A 20-Year Retrospective Analysis and Comparative Literature Review. 61
28977789 2018
50
Feline glioma: a retrospective study and review of the literature. 61
28156189 2017

Variations for Oligoastrocytoma

Expression for Oligoastrocytoma

Search GEO for disease gene expression data for Oligoastrocytoma.

Pathways for Oligoastrocytoma

GO Terms for Oligoastrocytoma

Sources for Oligoastrocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....